The evolving role of statins in the management of atherosclerosis.

By C. Vaughan, A. Gotto, C. Basson. Journal of the American College of Cardiology, 2000

625 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. (2006, background): “Lipid-lowering therapy with statins significantly dereases cardiovascular morbidity and mortality in primary nd secondary prevention (7,8).”
Pleiotropic effects of statins. (2005, background): “Recent studies suggest that statins possess antiinflammatory properties owing to their ability to reduce the number of inflammatory cells in atherosclerotic plaques (96).”
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms (2005, background): “Potential additional mechanisms include a reduction in the production of thromboxane A 2 and modifications in the cholesterol content of platelet membrane”
Statins: mechanism of action and effects (2001, background): “These effects were translated in significant cardiovascular morbidity and mortality reductions in many clinical trials (WOSCOPS, AFCAPS/TexCAPS, HS, CARE, LIPID, HPS) [1].”
Statins as a newly recognized type of immunomodulator (2000, background): “Statins are extensively used in medical practice, and large clinical trials have demonstrated that this class of lipid-lowering drugs greatly reduces cardiovascular-related morbidity and mortality in patients with and without coronary diseas”